Cargando…

Low-dose augmentation with buprenorphine increases emotional reactivity but not reward activity in treatment resistant mid- and late-life depression

Buprenorphine is currently being studied for treatment-resistant depression because of its rapid effect, relative safety, and unique pharmacodynamics. To understand the neural impact of buprenorphine in depression, we examined acute limbic and reward circuit changes during an intervention with low-d...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Chemin, Karim, Helmet T., Pecina, Marta, Aizenstein, Howard J., Lenze, Eric J., Blumberger, Daniel M., Mulsant, Benoit H., Kharasch, Evan D., Reynolds III, Charles F., Karp, Jordan F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356006/
https://www.ncbi.nlm.nih.gov/pubmed/30685701
http://dx.doi.org/10.1016/j.nicl.2019.101679
_version_ 1783391441342431232
author Lin, Chemin
Karim, Helmet T.
Pecina, Marta
Aizenstein, Howard J.
Lenze, Eric J.
Blumberger, Daniel M.
Mulsant, Benoit H.
Kharasch, Evan D.
Reynolds III, Charles F.
Karp, Jordan F.
author_facet Lin, Chemin
Karim, Helmet T.
Pecina, Marta
Aizenstein, Howard J.
Lenze, Eric J.
Blumberger, Daniel M.
Mulsant, Benoit H.
Kharasch, Evan D.
Reynolds III, Charles F.
Karp, Jordan F.
author_sort Lin, Chemin
collection PubMed
description Buprenorphine is currently being studied for treatment-resistant depression because of its rapid effect, relative safety, and unique pharmacodynamics. To understand the neural impact of buprenorphine in depression, we examined acute limbic and reward circuit changes during an intervention with low-dose buprenorphine augmentation pharmacotherapy. Mid and late-life adults with major depression (N = 31) who did not completely respond to an adequate trial of venlafaxine were randomized to augmentation with low-dose buprenorphine or matching placebo. We investigated early neural changes using functional magnetic resonance imaging (fMRI) from pre-randomization to 3 weeks using both an emotional reactivity task and a gambling task. We tested if: 1) there were significant neural changes acutely per intervention group, and 2) if acute neural changes were associated with depressive symptom change over 8 weeks using both the total score and the dysphoria subscale of the Montgomery Asberg Depression Rating Scale. Participants in both the buprenorphine and placebo groups showed similar changes in depressive symptoms. Neither the emotional reactivity nor gambling task resulted in significant neural activation changes from pre-randomization to 3-weeks. In both groups, increases in rostral anterior cingulate (rACC) and ventromedial prefrontal cortex (vmPFC) activation during the emotional reactivity task were associated with overall symptom improvement. In the buprenorphine but not the placebo group, increased activation in left anterior insula (aINS) and bilateral middle frontal gyrus (MFG) was associated with improvement on the dysphoria subscale. Activation changes in the reward task were not associated with buprenorphine. This is the first study to show an association between acute neural changes during emotion reactivity and changes in depression severity with buprenorphine treatment.
format Online
Article
Text
id pubmed-6356006
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-63560062019-02-08 Low-dose augmentation with buprenorphine increases emotional reactivity but not reward activity in treatment resistant mid- and late-life depression Lin, Chemin Karim, Helmet T. Pecina, Marta Aizenstein, Howard J. Lenze, Eric J. Blumberger, Daniel M. Mulsant, Benoit H. Kharasch, Evan D. Reynolds III, Charles F. Karp, Jordan F. Neuroimage Clin Regular Article Buprenorphine is currently being studied for treatment-resistant depression because of its rapid effect, relative safety, and unique pharmacodynamics. To understand the neural impact of buprenorphine in depression, we examined acute limbic and reward circuit changes during an intervention with low-dose buprenorphine augmentation pharmacotherapy. Mid and late-life adults with major depression (N = 31) who did not completely respond to an adequate trial of venlafaxine were randomized to augmentation with low-dose buprenorphine or matching placebo. We investigated early neural changes using functional magnetic resonance imaging (fMRI) from pre-randomization to 3 weeks using both an emotional reactivity task and a gambling task. We tested if: 1) there were significant neural changes acutely per intervention group, and 2) if acute neural changes were associated with depressive symptom change over 8 weeks using both the total score and the dysphoria subscale of the Montgomery Asberg Depression Rating Scale. Participants in both the buprenorphine and placebo groups showed similar changes in depressive symptoms. Neither the emotional reactivity nor gambling task resulted in significant neural activation changes from pre-randomization to 3-weeks. In both groups, increases in rostral anterior cingulate (rACC) and ventromedial prefrontal cortex (vmPFC) activation during the emotional reactivity task were associated with overall symptom improvement. In the buprenorphine but not the placebo group, increased activation in left anterior insula (aINS) and bilateral middle frontal gyrus (MFG) was associated with improvement on the dysphoria subscale. Activation changes in the reward task were not associated with buprenorphine. This is the first study to show an association between acute neural changes during emotion reactivity and changes in depression severity with buprenorphine treatment. Elsevier 2019-01-22 /pmc/articles/PMC6356006/ /pubmed/30685701 http://dx.doi.org/10.1016/j.nicl.2019.101679 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Regular Article
Lin, Chemin
Karim, Helmet T.
Pecina, Marta
Aizenstein, Howard J.
Lenze, Eric J.
Blumberger, Daniel M.
Mulsant, Benoit H.
Kharasch, Evan D.
Reynolds III, Charles F.
Karp, Jordan F.
Low-dose augmentation with buprenorphine increases emotional reactivity but not reward activity in treatment resistant mid- and late-life depression
title Low-dose augmentation with buprenorphine increases emotional reactivity but not reward activity in treatment resistant mid- and late-life depression
title_full Low-dose augmentation with buprenorphine increases emotional reactivity but not reward activity in treatment resistant mid- and late-life depression
title_fullStr Low-dose augmentation with buprenorphine increases emotional reactivity but not reward activity in treatment resistant mid- and late-life depression
title_full_unstemmed Low-dose augmentation with buprenorphine increases emotional reactivity but not reward activity in treatment resistant mid- and late-life depression
title_short Low-dose augmentation with buprenorphine increases emotional reactivity but not reward activity in treatment resistant mid- and late-life depression
title_sort low-dose augmentation with buprenorphine increases emotional reactivity but not reward activity in treatment resistant mid- and late-life depression
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356006/
https://www.ncbi.nlm.nih.gov/pubmed/30685701
http://dx.doi.org/10.1016/j.nicl.2019.101679
work_keys_str_mv AT linchemin lowdoseaugmentationwithbuprenorphineincreasesemotionalreactivitybutnotrewardactivityintreatmentresistantmidandlatelifedepression
AT karimhelmett lowdoseaugmentationwithbuprenorphineincreasesemotionalreactivitybutnotrewardactivityintreatmentresistantmidandlatelifedepression
AT pecinamarta lowdoseaugmentationwithbuprenorphineincreasesemotionalreactivitybutnotrewardactivityintreatmentresistantmidandlatelifedepression
AT aizensteinhowardj lowdoseaugmentationwithbuprenorphineincreasesemotionalreactivitybutnotrewardactivityintreatmentresistantmidandlatelifedepression
AT lenzeericj lowdoseaugmentationwithbuprenorphineincreasesemotionalreactivitybutnotrewardactivityintreatmentresistantmidandlatelifedepression
AT blumbergerdanielm lowdoseaugmentationwithbuprenorphineincreasesemotionalreactivitybutnotrewardactivityintreatmentresistantmidandlatelifedepression
AT mulsantbenoith lowdoseaugmentationwithbuprenorphineincreasesemotionalreactivitybutnotrewardactivityintreatmentresistantmidandlatelifedepression
AT kharaschevand lowdoseaugmentationwithbuprenorphineincreasesemotionalreactivitybutnotrewardactivityintreatmentresistantmidandlatelifedepression
AT reynoldsiiicharlesf lowdoseaugmentationwithbuprenorphineincreasesemotionalreactivitybutnotrewardactivityintreatmentresistantmidandlatelifedepression
AT karpjordanf lowdoseaugmentationwithbuprenorphineincreasesemotionalreactivitybutnotrewardactivityintreatmentresistantmidandlatelifedepression